bpc-157 fda warning news 2025 Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling An FDA Committee Just Voted

doi:10.1155/2020/6805354 Lee E, Padgett B

The current public schedule is: TRIUMPH-1: general obesity, 80-week treatment duration, the largest TRIUMPH trial, pivotal for the NDA filing

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid fragment derived from human gastric juice, first characterized by Sikiric and colleagues at the University of Zagreb 1

Peptides for visceral fat reduction have gained attention because visceral fat tends to respond differently than other types of body fat

Rapid absorption for quick results

Each compound is supplied in its own vial as a distinct reference material, not pre-mixed